Replication-Defective Vector Based on a Chimpanzee Adenovirus

ABSTRACT An adenovirus previously isolated from a mesenteric lymph node from a chimpanzee was fully sequenced and found to be similar in overall structure to human adenoviruses. The genome of this virus, called C68, is 36,521 bp in length and is most similar to subgroup E of human adenovirus, with 90% identity in most adenovirus type 4 open reading frames that have been sequenced. Substantial differences in the hexon hypervariable regions were noted between C68 and other known adenoviruses, including adenovirus type 4. Neutralizing antibodies to C68 were highly prevalent in sera from a population of chimpanzees, while sera from humans and rhesus monkeys failed to neutralize C68. Furthermore, infection with C68 was not neutralized from sera of mice immunized with human adenovirus serotypes 2, 4, 5, 7, and 12. A replication-defective version of C68 was created by replacing the E1a and E1b genes with a minigene cassette; this vector was efficiently transcomplemented by the E1 region of human adenovirus type 5. C68 vector transduced a number of human and murine cell lines. This nonhuman adenoviral vector is sufficiently similar to human serotypes to allow growth in 293 cells and transduction of cells expressing the coxsackievirus and adenovirus receptor. As it is dissimilar in regions such as the hexon hypervariable domains, C68 vector avoids significant cross-neutralization by sera directed against human serotypes.

[1]  P. Quax,et al.  Improved Adenovirus Vectors for Infection of Cardiovascular Tissues , 2001, Journal of Virology.

[2]  P. Hearing,et al.  Pseudopackaging of Adenovirus Type 5 Genomes into Capsids Containing the Hexon Proteins of Adenovirus Serotypes B, D, or E , 2001, Journal of Virology.

[3]  G. Stamatoyannopoulos,et al.  Efficient Gene Transfer into Human CD34+ Cells by a Retargeted Adenovirus Vector , 2000, Journal of Virology.

[4]  M. Lusky,et al.  Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products. , 2000, Human gene therapy.

[5]  R. M. Burnett,et al.  Type-specific epitope locations revealed by X-ray crystallographic study of adenovirus type 5 hexon. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  K. Propert,et al.  Immune responses to adenovirus and adeno-associated virus in humans , 1999, Gene Therapy.

[7]  C. Miller,et al.  An Adenovirus Vector with Genetically Modified Fibers Demonstrates Expanded Tropism via Utilization of a Coxsackievirus and Adenovirus Receptor-Independent Cell Entry Mechanism , 1998, Journal of Virology.

[8]  J. Gall,et al.  Construction and Characterization of Hexon-Chimeric Adenoviruses: Specification of Adenovirus Serotype , 1998, Journal of Virology.

[9]  JM Wilson,et al.  High throughput method for creating and screening recombinant adenoviruses , 1998, Gene Therapy.

[10]  M. Kaleko,et al.  Circumvention of Immunity to the Adenovirus Major Coat Protein Hexon , 1998, Journal of Virology.

[11]  D. Brough,et al.  Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins , 1997, Journal of virology.

[12]  A. Beaudet,et al.  Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors. , 1997, Human gene therapy.

[13]  P. Opolon,et al.  Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses , 1997, Journal of virology.

[14]  D. Farson,et al.  Persistent transgene expression in mouse liver following in vivo gene transfer with a ΔE1/ΔE4 adenovirus vector , 1997, Gene Therapy.

[15]  A. Pavirani,et al.  Humoral immune response to the capsid components of recombinant adenoviruses: Routes of immunization modulate virus‐induced Ig subclass shifts , 1997, European journal of immunology.

[16]  N. Guex,et al.  SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling , 1997, Electrophoresis.

[17]  J. Wilson,et al.  Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy , 1996, Journal of virology.

[18]  J. Leiden,et al.  Immune responses to transgene–encoded proteins limit the stability of gene expression after injection of replication–defective adenovirus vectors , 1996, Nature Medicine.

[19]  L. Leinwand,et al.  Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes , 1996, Journal of virology.

[20]  D. Schnurr,et al.  Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues , 1996, Journal of virology.

[21]  C. Basler,et al.  Subgroup B adenovirus type 35 early region 3 mRNAs differ from those of the subgroup C adenoviruses. , 1996, Virology.

[22]  M. Weitzman,et al.  Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis , 1996, Journal of virology.

[23]  K. Kurachi,et al.  Adenovirus-mediated transfer of human factor IX gene in immunodeficient and normal mice: evidence for prolonged stability and activity of the transgene in liver. , 1996, Viral immunology.

[24]  A. Pavirani,et al.  Long‐term humoral and cellular immunity induced by a single immunization with replication‐defective adenovirus recombinant vector , 1995, European journal of immunology.

[25]  G. Trinchieri,et al.  Recombinant IL–12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung , 1995, Nature Medicine.

[26]  J. Whitsett,et al.  Persistence of replication-deficient adenovirus-mediated gene transfer in lungs of immune-deficient (nu/nu) mice. , 1995, Human gene therapy.

[27]  H. Ertl,et al.  Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses , 1995, Journal of virology.

[28]  R. M. Burnett,et al.  The refined crystal structure of hexon, the major coat protein of adenovirus type 2, at 2.9 A resolution. , 1994, Journal of molecular biology.

[29]  H. Ertl,et al.  MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. , 1994, Immunity.

[30]  J. Wilson,et al.  In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. , 1994, The Journal of biological chemistry.

[31]  T. Adrian,et al.  Chimpanzee adenoviruses are related to four subgenera of human adenoviruses. , 1989, Intervirology.

[32]  P. Sharp,et al.  Generation of adenovirus by transfection of plasmids. , 1983, Nucleic acids research.

[33]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[34]  G. Kitchingman.  Restriction mapping and molecular cloning of adenovirus type 4 (subgroup E) DNA. , 1982, Gene.

[35]  S. Kalter,et al.  Immunological relationship among adenoviruses of humans, simians, and nonprimates as determined by the neutralization test. , 1981, Intervirology.

[36]  F. Graham,et al.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5. , 1977, The Journal of general virology.

[37]  D. Gajdusek,et al.  Characterization of four new adenovirus serotypes isolated from chimpanzee tissue explants. , 1971, American journal of epidemiology.